ORIGINAL ARTICLE

A new hope of CD133+ bone marrow stem cell for functional exercise capacity improvement in low ejection fraction coronary artery bypass graft patients: a clinical trial

Tri Wisesa Soetisna

Tri Wisesa Soetisna
Department of Cardiothoracic and Vascular Surgery, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia ; Department of Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. Email: [email protected]
Online First: April 28, 2021 | Cite this Article
Soetisna, T. 2021. A new hope of CD133+ bone marrow stem cell for functional exercise capacity improvement in low ejection fraction coronary artery bypass graft patients: a clinical trial. Bali Medical Journal 10(1): 229-233. DOI:10.15562/bmj.v10i1.2255


Background: Patients with low ejection fraction who are undergoing coronary artery bypass graft (CABG) only have an insignificant improvement in ejection fraction. This condition will make a little hope to achieve an improvement in physical performance. But now, from a view study, CD133+ stem cells offer new hope for this situation. This study evaluates CD133+ bone marrow stem cells' role for functional exercise capacity improvement in low ejection fraction coronary artery bypass graft patients.

Methods: Thirty patients with ischemic heart disease who had ejection fraction <35% at the National Cardiovascular Center were randomized into 2 groups. The treatment group undergoes the CABG + CD133+ procedure and the control group undergoes the CABG only. All research subjects underwent follow-up before and 6 months after the procedure. Fraction ejection, scar size, wall motion score index, ventricular dimensions, myocardial perfusion measured by cardiac MRI, 6 Minutes Walking Test (6MWT) and Minnesota Living with Heart Failure Questionnaire (MLHFQ) as an additional parameter for physical performance and quality of life. Data was analyzed using SPSS version 21 for Windows.

Results: The results of the fraction ejection parameters showed a significant improvement in the treatment group, from 25.88±5.66% to 34.57%±11.31% compared to CABG only 30.18±3.85% to 31.61±7.89% (p=0.040), in the perfusion defect showed improvement but not significant, left ventricular end-systolic volume and left ventricular end-diastolic volume showed improvement with no significant result, scar size was found to be an improvement in the treatment group 10 persons (76.92%) compared to the control group 5 persons (38, 46%) (p=0.040), the wall motion score index and 6MWT showed a significant improvement in the treatment group (p=0.003 and p=0.03, respectively). The MLHFQ parameter showed improvement but not significant.

Conclusion: CD 133+ stem cell implantation in patients with low ejection fraction who undergo CABG provides improved myocardial function and indirectly improves functional exercise capacity and patients' quality of life.

References

Haxhibeqiri-Karabdic I, Hasanovic A, Kabil E, Straus S. Improvement of ejection fraction after coronary artery bypass grafting surgery in patients with impaired left ventricular function. Med Arch (Sarajevo, Bosnia Herzegovina). 2014;68(5):332–4. DOI: 10.5455/medarh.2014.68.332-334

Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res. 2004;95(4):343–53. DOI: 10.1161/01.RES.0000137877.89448.78.

Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: Safety and efficacy studies. J Thorac Cardiovasc Surg. 2007;133(3). DOI: 10.1016/j.jtcvs.2006.08.077

Han C, Sun X, Liu L, Jiang H, Shen Y, Xu X, et al. Exosomes and their therapeutic potentials of stem cells. Stem Cells Int. 2016;2016. DOI: 10.1155/2016/7653489

Van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol [Internet]. 2018;19(4):213–28. Available from: DOI: 10.1038/nrm.2017.125

Barzegar Behrooz A, Syahir A, Ahmad S. CD133: beyond a cancer stem cell biomarker. J Drug Target [Internet]. 2019;27(3):257–69. DOI: 10.1080/1061186X.2018.1479756

Nasseri BA, Ebell W, Dandel M, Kukucka M, Gebker R, Doltra A, et al. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: The Cardio133 trial. Eur Heart J. 2014;35(19):1263–74. DOI: 10.1093/eurheartj/ehu007

Alan W. Heldman, MD Darcy L. DiFede, RN, BSN, Joel E Fishman, MD, , Juan P. Zambrano, MD, Barry H. Trachtenberg, MD, Vasileios Karantalis, MD, Muzammil Mushtaq, MD, Adam R. Williams, MD, Viky Y. Suncion, MD, Ian K. McNiece, PhD. Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy: The TAC-HFT Randomized Trial. JAMA. 2014;311(1):62–73. DOI: 10.1001/jama.2013.282909

Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, et al. Cardiopoietic stem cell therapy in heart failure: The C-CURE (cardiopoietic stem cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329–38. DOI: 10.1016/j.jacc.2013.02.071

Beck KC, Randolph LN, Bailey KR, Wood CM, Snyder EM, Johnson BD. Relationship between cardiac output and oxygen consumption during upright cycle exercise in healthy humans. J Appl Physiol. 2006;101(5):1474–80. DOI: 10.1152/japplphysiol.00224.2006


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0